Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)

Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)

Nov 13, 2022

Jeffrey Curtis1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1University of Alabama at Birmingham, Hoover, AL, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA...
Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis

Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis

Jun 1, 2022

 Johanna Withers, PhD; Lixia Zhang, PhD; Sam Asgarian, MD Presented at EULAR 2022 Copenhagen, Denmark – June 1-4, 2022 Background: Despite drug therapies that improve lives, tens of millions of patients annually are subjected to therapy using a...
‘A ton of hurdles’ stand in the way of precision medicine for rheumatoid arthritis

Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis

Apr 23, 2022

Vibeke Strand; Lixia Zhang; Alix Arnaud; Erin Connolly-Strong; Sam Asgarian & Johanna B Withers Background A blood-based molecular signature response classifier (MSRC) predicts non-response to tumor necrosis factor-ɑ inhibitors (TNFi) in rheumatoid arthritis (RA)....
‘A ton of hurdles’ stand in the way of precision medicine for rheumatoid arthritis

Scipher Medicine Closes $110 Million Financing

Feb 24, 2022

Cowen Healthcare Investments leads the round Additional new investors include Neuberger Berman, Hitachi Ventures, Laurion Capital, and Monashee Investment Management Returning investors include Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo...